Research ArticleLiver disease

Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis

See allHide authors and affiliations

Science Translational Medicine  27 Nov 2019:
Vol. 11, Issue 520, eaav9701
DOI: 10.1126/scitranslmed.aav9701

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

A pill a day keeps liver fat away

Nonalcoholic fatty liver diseases can progress to liver failure but currently lack approved treatments. Amin et al. tested the therapeutic efficacy of a small-molecule inhibitor of diacylglycerol acyltransferase 2 (DGAT2; responsible for hepatic triglyceride production) in rodent models of nonalcoholic steatohepatitis and found that PF-06427878 improved liver steatosis and function. Two phase 1 clinical trials in healthy humans showed improved markers of liver function at the highest dose administered. One of the clinical trials measured liver fat and demonstrated its reduction in healthy participants on the highest dose. PF-06427878 may be a candidate to treat conditions related to fatty liver in humans.

View Full Text